Firazyr FDA Approval History
FDA Approved: Yes (First approved August 25, 2011)
Brand name: Firazyr
Generic name: icatibant
Dosage form: Injection
Company: Shire plc
Treatment for: Angioedema
Firazyr (icatibant) is a selective B2 bradykinin receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema.
Development timeline for Firazyr
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.